FARON PHARMACEUTICALS OY

Report Publication Announcement • Feb 10, 2016

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 5836O

Faron Pharmaceuticals Oy

10 February 2016

Faron Pharmaceuticals Ltd

("Faron" or the "Company")

Notice of Preliminary Results

TURKU - FINLAND, 10 February 2016 - Faron Pharmaceuticals Ltd ("Faron") (LON: FARN), the clinical stage biopharmaceutical company, will announce its Preliminary Results for the year ended 31st December, 2015 on Thursday 10th March, 2016.

Dr Markku Jalkanen, Chief Executive Officer, will host a presentation for analysts at 9am GMT on the day at Hume Brophy offices, 55 King William Street, London EC4R 9AD.

For more information contact:

Faron Pharmaceuticals Ltd

Katja Wallenlind

Phone +358 (50) 577 4807

E-mail: katja.wallenlind@faronpharmaceuticals.com

Cairn Financial Advisers LLP, Nominated Adviser

Emma Earl, Tony Rawlinson and Rebecca Anderson

Phone: +44 207 148 7900

Whitman Howard Limited, Nominated Broker

Niall Devins, Francis North

Phone: +44 207 659 1234

Hume Brophy, PR

Mary Clark, Eva Haas, Hollie Vile

Phone: +44 207 862 6390

E-mail: faron@humebrophy.com

About Faron Pharmaceuticals Oy

Faron is a drug discovery and development company focused on creating novel treatments for medical conditions with significant unmet needs. The Company is based in Turku, Finland. The Company currently has a pipeline of products focusing on acute organ traumas, cancer immunotherapy and vascular damage. The Company's lead candidate Traumakine®, has been developed to treat acute respiratory distress syndrome ("ARDS"), a rare, severe, life threatening medical condition for which there is currently no approved pharmaceutical treatment. Traumakine® is now in a pan-European pivotal Phase III study (INTEREST). Besides Traumakine®, Faron's pipeline consists of early stage assets including a pre-clinical anti-Clever-1 antibody named Clevegen. Clevegen is focused on converting the immune environment around a tumour from being immune suppressive to immune stimulating.

Further information is available at www.faronpharmaceuticals.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NORVKLFBQLFEBBF